Clinical Trial Update: Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Cardenilimab plus lenvatinib for perioperative, resectable clear cell renal cell carcinoma; the study status is NOT_YET_RECR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Cardenilimab
• Lenvatinib (lenvatinib)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Resectable Clear Cell Carcinoma of the Kidney | Phase 2 | Status: NOT_YET_RECRUITING